LH Stock Chart & Stats
$4705.14
$0.00(0.00%)
At close: 4:00 PM EDT
$4705.14
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$3,000.00 - $5,245.61
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$450.04B
Enterprise Value$29.60K
Total Cash (Recent Filing)$141.80M
Total Debt (Recent Filing)$6.77B
Price to Earnings (P/E)26.9
Beta0.20
Next Earnings
Oct 22, 2026EPS Estimate
80.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)12.17
Shares Outstanding81,100,000
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio1.28
Price to Book (P/B)2.42
Price to Sales (P/S)1.50
P/FCF Ratio17.31
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$5,730.65Price Target Upside21.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)311.77
Revenue Forecast (FY)$250.76B
Bulls Say, Bears Say
Bulls Say
Revenue And Margin ExpansionBroad revenue growth and improved operating leverage indicate stronger execution across Labcorp’s platforms. Sustained volume, mix and productivity gains could support earnings growth over the next several quarters.
Biopharma Backlog VisibilityThe sizeable backlog and positive book-to-bill provide meaningful forward revenue visibility for Drug Development. This supports capacity planning, customer retention and more predictable growth despite uneven clinical-trial activity.
Expansion Of Specialty DiagnosticsAdding the first FDA-cleared single-biomarker blood test that can rule in and rule out amyloid pathology expands Labcorp’s specialty diagnostics offering. It may deepen provider relationships and support higher-value testing adoption.
Bears Say
Margins Below Historical PeakAlthough profitability is improving, margins remain well below prior peak levels, showing that the recovery is incomplete. Continued wage, reimbursement and operating-cost pressure could limit the durability of earnings growth.
Leverage And Cash FlexibilityMeaningful absolute debt combined with relatively low cash reduces financial flexibility if demand softens or investment needs rise. The recent free-cash-flow decline and imperfect earnings conversion further constrain debt reduction capacity.
PAMA Regulatory UncertaintyPotential changes to laboratory reimbursement under PAMA could pressure realized pricing and Diagnostics profitability. Uncertainty over implementation or delays makes long-term planning harder and may keep payer-policy risk elevated.
Labcorp Holdings News
LH FAQ
What was Labcorp Holdings’s price range in the past 12 months?
Labcorp Holdings lowest stock price was $3000.00 and its highest was $5245.61 in the past 12 months.
What is Labcorp Holdings’s market cap?
Labcorp Holdings’s market cap is $450.04B.
When is Labcorp Holdings’s upcoming earnings report date?
Labcorp Holdings’s upcoming earnings report date is Oct 22, 2026 which is in 44 days.
How were Labcorp Holdings’s earnings last quarter?
Labcorp Holdings released its earnings results on Jul 30, 2026. The company reported $85.849 earnings per share for the quarter, beating the consensus estimate of $82.219 by $3.63.
Is Labcorp Holdings overvalued?
According to Wall Street analysts Labcorp Holdings’s price is currently Undervalued.
Does Labcorp Holdings pay dividends?
Labcorp Holdings does not currently pay dividends.
What is Labcorp Holdings’s EPS estimate?
Labcorp Holdings’s EPS estimate is 80.05.
How many shares outstanding does Labcorp Holdings have?
Labcorp Holdings has 81,100,000 shares outstanding.
What happened to Labcorp Holdings’s price movement after its last earnings report?
Labcorp Holdings reported an EPS of $85.849 in its last earnings report, beating expectations of $82.219. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Labcorp Holdings?
Currently, no hedge funds are holding shares in MX:LH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Labcorp Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5,730.65 (21.80% Upside)
$5,730.65 (21.80% Upside)
Blogger Sentiment
Neutral
MX:LH Sentiment 75%
Sector Average 60%
Sector Average 60%
Insider Transactions
Sold Shares
Worth $12.3M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
19.97%
12-Months-Change
Fundamentals
Return on Equity
0.86%
Trailing 12-Months
Asset Growth
2.62%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Labcorp Holdings
Labcorp Holdings, Inc. offers vital diagnostic laboratory services, enabling medical professionals, healthcare facilities, pharmaceutical firms, scientific investigators, and patients to make well-informed and confident choices. The company commenced operations on April 16, 2024, and its main office is situated in Burlington, NC.
LH Company Deck
LH Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a strong operational and financial quarter: revenue growth, margin expansion, double-digit adjusted EPS growth, raised guidance, robust BLS backlog and book-to-bill, and multiple product/partnership launches. Headwinds highlighted were a meaningful quarter-over-quarter drop in free cash flow (timing and capex), a modest ACA-related volume headwind (~30 bps), prior and improving Early Development softness, higher patient-pay mix, and elevated absolute debt with relatively low cash on hand. On balance the positives around revenue, margins, guidance increases, product/market progress, and capital returns materially outweigh the cited challenges.View all MX:LH earnings summariesLH Revenue Breakdown
77.96% Dx
22.21% BLS
-0.16% Intercompany eliminations
LH Stock 12 Month Forecast
Average Price Target
$5,730.65
▲(21.80% Upside)